You are here: Industry Insights > Venclyxto

News List

Imbruvica/Venclyxto tops Gazyva plus chemo in first-line CLL/SLL pharmatimes
June 17, 2021
Johnson & Johnson’s BTK inhibitor Imbruvica plus AbbVie and Roche’s Vencylxto demonstrated superiority over Gazyva plus chemotherapy in a new Phase III study.
MHRA approves Venclyxto for newly diagnosed AML pharmatimes
June 16, 2021
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved AbbVie and Roche’s Venclyxto for the treatment of newly diagnosed acute myeloid leukaemia (AML).
Chemotherapy-free combination shows potential in lymphocytic leukaemia trial europeanpharmaceuticalreview
June 09, 2021
Imbruvica® (ibrutinib) plus Venclexta®/Venclyxto® (venetoclax) resulted in 95 percent of chronic lymphocytic leukaemia patients surviving without disease progression for two years.
European Commission approves Venclyxto-based combinations for adults with newly diagnosed acute myeloid leukaemia worldpharmanews
May 26, 2021
Roche announced that the European Commission has approved Venclyxto® (venetoclax) in combination with hypomethylating agents, azacitidine and decitabine, for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) who are ...
AbbVie's Venclyxto shows promise as AML treatment pharmatimes
June 17, 2020
AbbVie has presented new data showing the potential of Venclyxto (venetoclax) to reduce the risk of death in previously untreated patients with acute myeloid leukaemia (AML) who were ineligible for intensive chemotherapy.
Venclexta/Venclyxto combo extends myeloid leukaemia survival pharmatimes
March 25, 2020
Roche has announced that its Phase III VIALE-A study, evaluating Venclexta/Venclyxto (venetoclax) in combination with azacitidine for acute myeloid leukaemia (AML), has met its dual primary endpoints.
AbbVie Receives EC Approval of VENCLYXTO Regimen for Lymphocytic Leukemia americanpharmaceuticalreview
March 16, 2020
AbbVie announced the European Commission (EC) has approved VENCLYXTO® (venetoclax) in combination with obinutuzumab for the treatment of adult patients with chronic lymphocytic leukemia (CLL) ...
Venclyxto gains approval in Europe pharmatimes
March 16, 2020
The European Commission has approved Venclyxto (venetoclax) in combination with Gazyvaro (obinutuzumab) for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL).
AbbVie’s CLL drug Venclyxto too expensive for NHS, says NICE pharmaphorum
December 19, 2018
NICE has said AbbVie’s Venclyxto (venetoclax), in combination with development partner Roche’s MabThera/Rituxan (rituximab), is not a cost-effective use of NHS resources as a treatment for a kind of leukaemia.
AbbVie's Venclyxto combo beats standard of care in chronic lymphocytic leukaemia pharmafile
December 04, 2018
AbbVie has taken the opportunity at the American Society of Hematology (ASH) Annual Meeting 2018 to reveal new data on venetoclax (Venclyxto) in combination with rituximab (VenR), in which it demonstrated

Previous page 1 2 Next page